Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1 1

Status

Completed 2Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Gastrointestinal 1Breast 1

Conditions

Glioma 1Glioblastoma 1Brain Neoplasms 1

Interventions

Temozolomide 299Radiotherapy 219Bevacizumab 139Carboplatin 91Cyclophosphamide 88Etoposide 82Filgrastim 72Vincristine 69Irinotecan 69Magnetic Resonance Spectroscopy 64Cisplatin 59Radiation 58Radiosurgery 52Surgical Procedures, Operative 41Peripheral Blood Stem Cell Transplantation 40Topotecan 39Doxorubicin 39Lomustine 37Carmustine 36sargramostim 35Granulocyte Colony-Stimulating Factor 35Melphalan 34Nivolumab 32Chemotherapy, Adjuvant 32Radiotherapy, Intensity-Modulated 29Isotretinoin 29Everolimus 29Erlotinib Hydrochloride 27Thiotepa 25Vorinostat 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Sulfasalazine × CNS × Clear all
NCT04205357 2023-03-03

SAS-GKRS

Haukeland University Hospital

Phase 1 Completed
24 enrolled
CNS

Glioblastoma, Glioma

NCT01577966 2016-12-08

Pilot Study Effect of Sulfasalazine on Glutamate Levels by(Magnetic Resonance Spectroscopy)MRS in Patients With Glioma

University of Alabama at Birmingham

Phase NA Completed
9 enrolled 4 charts
CNS

Brain Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡